These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
139 related articles for article (PubMed ID: 31022583)
1. Cucurbitacins inspired organic synthesis: Potential dual inhibitors targeting EGFR - MAPK pathway. Mahnashi M; Elgazwi SM; Ahmed MS; Halaweish FT Eur J Med Chem; 2019 Jul; 173():294-304. PubMed ID: 31022583 [TBL] [Abstract][Full Text] [Related]
2. Design, synthesis and biological study of hybrid drug candidates of nitric oxide releasing cucurbitacin-inspired estrone analogs for treatment of hepatocellular carcinoma. Abou-Salim MA; Shaaban MA; Abd El Hameid MK; Elshaier YAMM; Halaweish F Bioorg Chem; 2019 Apr; 85():515-533. PubMed ID: 30807895 [TBL] [Abstract][Full Text] [Related]
3. Cucurbitacin IIa interferes with EGFR-MAPK signaling pathway leads to proliferation inhibition in A549 cells. Zhang J; Song Y; Liang Y; Zou H; Zuo P; Yan M; Jing S; Li T; Wang Y; Li D; Zhang T; Wei Z Food Chem Toxicol; 2019 Oct; 132():110654. PubMed ID: 31265865 [TBL] [Abstract][Full Text] [Related]
4. Novel series of 6-(2-substitutedacetamido)-4-anilinoquinazolines as EGFR-ERK signal transduction inhibitors in MCF-7 breast cancer cells. Ismail RSM; Abou-Seri SM; Eldehna WM; Ismail NSM; Elgazwi SM; Ghabbour HA; Ahmed MS; Halaweish FT; Abou El Ella DA Eur J Med Chem; 2018 Jul; 155():782-796. PubMed ID: 30047410 [TBL] [Abstract][Full Text] [Related]
5. Biological screening of cucurbitacin inspired estrone analogs targeting mitogen-activated protein kinase (MAPK) pathway. Ahmed MS; El-Senduny F; Taylor J; Halaweish FT Chem Biol Drug Des; 2017 Sep; 90(3):478-484. PubMed ID: 28171685 [TBL] [Abstract][Full Text] [Related]
6. In silico design, synthesis and activity of potential drug-like chrysin scaffold-derived selective EGFR inhibitors as anticancer agents. Debnath S; Kanakaraju M; Islam M; Yeeravalli R; Sen D; Das A Comput Biol Chem; 2019 Dec; 83():107156. PubMed ID: 31710991 [TBL] [Abstract][Full Text] [Related]
7. Structural optimization and biological screening of a steroidal scaffold possessing cucurbitacin-like functionalities as B-Raf inhibitors. Ahmed MS; Kopel LC; Halaweish FT ChemMedChem; 2014 Jul; 9(7):1361-7. PubMed ID: 24682977 [TBL] [Abstract][Full Text] [Related]
8. Discovery of novel dual inhibitors of receptor tyrosine kinases EGFR and PDGFR-β related to anticancer drug resistance. Fischer T; Najjar A; Totzke F; Schächtele C; Sippl W; Ritter C; Hilgeroth A J Enzyme Inhib Med Chem; 2018 Dec; 33(1):1-8. PubMed ID: 29098884 [TBL] [Abstract][Full Text] [Related]
9. Cucurbitacins: potential candidates targeting mitogen-activated protein kinase pathway for treatment of melanoma. Ahmed MS; Halaweish FT J Enzyme Inhib Med Chem; 2014 Apr; 29(2):162-7. PubMed ID: 23368732 [TBL] [Abstract][Full Text] [Related]
10. Novel pyrazolo[3,4-d]pyrimidines: design, synthesis, anticancer activity, dual EGFR/ErbB2 receptor tyrosine kinases inhibitory activity, effects on cell cycle profile and caspase-3-mediated apoptosis. Maher M; Kassab AE; Zaher AF; Mahmoud Z J Enzyme Inhib Med Chem; 2019 Dec; 34(1):532-546. PubMed ID: 30688116 [TBL] [Abstract][Full Text] [Related]
11. Novel thienopyrimidine derivatives as dual EGFR and VEGFR-2 inhibitors: design, synthesis, anticancer activity and effect on cell cycle profile. Mghwary AE; Gedawy EM; Kamal AM; Abuel-Maaty SM J Enzyme Inhib Med Chem; 2019 Dec; 34(1):838-852. PubMed ID: 30919701 [TBL] [Abstract][Full Text] [Related]
12. Design, synthesis and evaluation of acridine derivatives as multi-target Src and MEK kinase inhibitors for anti-tumor treatment. Cui Z; Li X; Li L; Zhang B; Gao C; Chen Y; Tan C; Liu H; Xie W; Yang T; Jiang Y Bioorg Med Chem; 2016 Jan; 24(2):261-9. PubMed ID: 26707846 [TBL] [Abstract][Full Text] [Related]
13. Design, synthesis and biological evaluation of novel 4-anlinoquinazoline derivatives as EGFR inhibitors with the potential to inhibit the gefitinib-resistant nonsmall cell lung cancers. Wang C; Xu S; Peng L; Zhang B; Zhang H; Hu Y; Zheng P; Zhu W J Enzyme Inhib Med Chem; 2019 Dec; 34(1):203-217. PubMed ID: 30835140 [TBL] [Abstract][Full Text] [Related]
14. Novel sulphonamide benzoquinazolinones as dual EGFR/HER2 inhibitors, apoptosis inducers and radiosensitizers. Soliman AM; Alqahtani AS; Ghorab M J Enzyme Inhib Med Chem; 2019 Dec; 34(1):1030-1040. PubMed ID: 31074303 [TBL] [Abstract][Full Text] [Related]
15. Synthesis and antitumor evaluation of novel 4-anilino-7,8-dihydropyrido[4,3-d]pyrimidine-6(5H)-carboxylate derivatives as potential EGFR inhibitors. Zhang D; Yan Y; Jin G; Liu B; Ma X; Han D; Jia X Arch Pharm (Weinheim); 2018 Sep; 351(9):e1800110. PubMed ID: 30048007 [TBL] [Abstract][Full Text] [Related]
16. Synthesis, EGFR Inhibition and Anti-cancer Activity of New 3,6-dimethyl-1-phenyl-4-(substituted-methoxy)pyrazolo[3,4-d] pyrimidine Derivatives. Bakr RB; Mehany ABM; Abdellatif KRA Anticancer Agents Med Chem; 2017; 17(10):1389-1400. PubMed ID: 28270084 [TBL] [Abstract][Full Text] [Related]
17. Pyrrolidino Analogues of Gefitinib with Improved EGFR Inhibition, Cancer Cell Cytotoxicity, and Pharmacokinetic Properties. Fang JK; Xu Z; Zhang Y; Zhang W; Liu B; Fang Y; Sun T Anticancer Agents Med Chem; 2016; 16(12):1665-1672. PubMed ID: 27349449 [TBL] [Abstract][Full Text] [Related]
18. Triazole-estradiol analogs: A potential cancer therapeutic targeting ovarian and colorectal cancer. Ostlund T; Alotaibi F; Kyeremateng J; Halaweish H; Kasten A; Iram S; Halaweish F Steroids; 2022 Jan; 177():108950. PubMed ID: 34933058 [TBL] [Abstract][Full Text] [Related]
19. Cucurbitacin IIb induces apoptosis and cell cycle arrest through regulating EGFR/MAPK pathway. Liang Y; Zhang T; Ren L; Jing S; Li Z; Zuo P; Li T; Wang Y; Zhang J; Wei Z Environ Toxicol Pharmacol; 2021 Jan; 81():103542. PubMed ID: 33161110 [TBL] [Abstract][Full Text] [Related]
20. Carnosic Acid, Tangeretin, and Ginkgolide-B Anti-neoplastic Cytotoxicity in Dual Combination with Dexamethasone-[anti-EGFR] in Pulmonary Adenocarcinoma (A549). Coyne CP; Narayanan L Anticancer Agents Med Chem; 2019; 19(6):802-819. PubMed ID: 30514195 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]